Congenital Hypothyroidism and Bone Remodeling Cycle

J Clin Res Pediatr Endocrinol. 2017 Jun 1;9(2):106-110. doi: 10.4274/jcrpe.3532. Epub 2016 Nov 9.

Abstract

Objective: The present study aimed to evaluate the biochemical markers of bone turnover in children with congenital hypothyroidism during the course of treatment as compared to healthy children selected as controls.

Methods: The study included 31 children with congenital hypothyroidism and 29 healthy children. In both groups, we evaluated serum procollagen type-1 N-terminal propeptide (PINP) and tartrate-resistant acid phosphatase type 5b isoform (TRACP 5b) levels as bone turnover markers.

Results: In both groups, thyroid hormone levels were within normal limits. The levels of vitamin D were significantly higher in the cases with congenital hypothyroidism. Although PINP levels were not found to be different, TRACP 5b levels which are related to osteoclastic activities were significantly higher in the control group.

Conclusion: We did not detect an increase in bone resorption in patients with congenital hypothyroidism, despite long-term treatment with LT4. Our results suggest that with effective vitamin D treatment and thyroxin replacement, congenital hypothyroidism is not a deleterious factor for bone turnover.

Keywords: Congenital hypothyroidism; bone marker thyroxin..

MeSH terms

  • Biomarkers / blood*
  • Bone Density Conservation Agents / therapeutic use
  • Bone Remodeling / drug effects*
  • Child
  • Child, Preschool
  • Congenital Hypothyroidism / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Peptide Fragments / blood*
  • Procollagen / blood*
  • Tartrate-Resistant Acid Phosphatase / blood*
  • Thyroxine / therapeutic use
  • Vitamin D / therapeutic use

Substances

  • Biomarkers
  • Bone Density Conservation Agents
  • Peptide Fragments
  • Procollagen
  • procollagen Type I N-terminal peptide
  • Vitamin D
  • ACP5 protein, human
  • Tartrate-Resistant Acid Phosphatase
  • Thyroxine